STARPHARMA HLDG.SP.ADR/10 (PQ6A) - Total Assets
Based on the latest financial reports, STARPHARMA HLDG.SP.ADR/10 (PQ6A) holds total assets worth €25.42 Million EUR (≈ $29.72 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See STARPHARMA HLDG.SP.ADR/10 net asset quality index to measure how much of total assets are equity-financed.
STARPHARMA HLDG.SP.ADR/10 - Total Assets Trend (2022–2025)
This chart illustrates how STARPHARMA HLDG.SP.ADR/10's total assets have evolved over time, based on quarterly financial data. See net assets of STARPHARMA HLDG.SP.ADR/10 for net asset value and shareholders' equity analysis.
STARPHARMA HLDG.SP.ADR/10 - Asset Composition Analysis
Current Asset Composition (June 2025)
STARPHARMA HLDG.SP.ADR/10's total assets of €25.42 Million consist of 88.8% current assets and 11.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 60.6% |
| Accounts Receivable | €4.04 Million | 15.9% |
| Inventory | €1.92 Million | 7.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how STARPHARMA HLDG.SP.ADR/10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PQ6A market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: STARPHARMA HLDG.SP.ADR/10's current assets represent 88.8% of total assets in 2025, a decrease from 91.7% in 2022.
- Cash Position: Cash and equivalents constituted 60.6% of total assets in 2025, down from 75.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 15.9% of total assets.
STARPHARMA HLDG.SP.ADR/10 Competitors by Total Assets
Key competitors of STARPHARMA HLDG.SP.ADR/10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
USA | $279.04 Million |
|
Neurotech International Ltd
AU:NTI
|
Australia | AU$6.81 Million |
|
Uniqure NV
NASDAQ:QURE
|
USA | $888.38 Million |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
USA | $571.00K |
|
Kura Oncology Inc
NASDAQ:KURA
|
USA | $652.55 Million |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
USA | $109.20 Million |
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
USA | $279.84 Million |
|
Isofol Medical AB
ST:ISOFOL
|
Sweden | Skr129.40 Million |
STARPHARMA HLDG.SP.ADR/10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.32 | 4.94 | - |
| Quick Ratio | 3.95 | 4.58 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €17.33 Million | €26.26 Million | - |
STARPHARMA HLDG.SP.ADR/10 - Advanced Valuation Insights
This section examines the relationship between STARPHARMA HLDG.SP.ADR/10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.50 |
| Latest Market Cap to Assets Ratio | 3.90 |
| Asset Growth Rate (YoY) | -30.9% |
| Total Assets | €25.42 Million |
| Market Capitalization | $99.13 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values STARPHARMA HLDG.SP.ADR/10's assets at a significant premium (3.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: STARPHARMA HLDG.SP.ADR/10's assets decreased by 30.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for STARPHARMA HLDG.SP.ADR/10 (2022–2025)
The table below shows the annual total assets of STARPHARMA HLDG.SP.ADR/10 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €25.42 Million ≈ $29.72 Million |
-30.95% |
| 2024-06-30 | €36.81 Million ≈ $43.04 Million |
-29.32% |
| 2023-06-30 | €52.09 Million ≈ $60.89 Million |
-21.29% |
| 2022-06-30 | €66.17 Million ≈ $77.37 Million |
-- |
About STARPHARMA HLDG.SP.ADR/10
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more